ASH
The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies.
Researchers Test Single-Cell Whole-Genome Sequencing to Select Therapy in Relapsed Multiple Myeloma
Premium
At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.
Adaptive Biotechnologies' MRD Test May Allow Some Mantle Cell Lymphoma Patients to Skip Transplant
Premium
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission compared to Rituxan alone, a study showed.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on investigational candidates.
The data suggest that multiple myeloma patients on Janssen's CAR T-cell therapy lived longer than on BMS's but experienced more severe side effects.